The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite

Prognostic variables in node-negative and node-positive breast cancer - Introduction

By Gasparini G.  

Breast Cancer Research and Treatment, Vol. 51, Iss. 3, 1998-10 ,pp. : 193-194

Springer Publishing Company

Access to resources Recommend Favorite

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

By Melisko Michelle  

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 45-47

Informa Healthcare

Access to resources Recommend Favorite

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

By Naoi Yasuto  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite

TP53 Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer

By Overgaard Jens   Yilmaz Mette   Guldberg Per   Hansen Lise Lotte   Alsner Jan  

Acta Oncologica, Vol. 39, Iss. 3, 2000-10 ,pp. : 327-333

Informa Healthcare

Access to resources Recommend Favorite